Patents by Inventor Søren OTTOSEN
Søren OTTOSEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220042022Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.Type: ApplicationFiled: August 17, 2021Publication date: February 10, 2022Inventors: Rubén Alvarez Sánchez, Roberto Iacone, Peter Hagedorn, Susanne Kammler, Søren Ottosen, Sindri Traustason, Heidi Rye Hudlebusch, Lykke Pedersen, Marco Berrera, Andreas Dieckmann
-
Publication number: 20220031730Abstract: The present invention relates to enhanced antisense oligonucleotides that are complementary to the Far Upstream Element-Binding Protein 1 (FUBP1) and are capable of reducing a FUBP1 target nucleic acid, such as FUBP1 mRNA. The invention relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. The invention in particular relates to the use of the enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for destabilizing cccDNA, such as HBV cccDNA. The invention further relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating cancer. A pharmaceutical composition and its use in the treatment and/or prevention of an HBV infection, or its use in the treatment of cancer is also disclosed.Type: ApplicationFiled: June 25, 2021Publication date: February 3, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Sabine SEWING, Søren OTTOSEN, Jacob RAVN, Lykke PEDERSEN, Souphalone LUANGSAY, Erich KOLLER, Johanna Marie WALTHER, Helene Maria GYLLING, Natascha HRUSCHKA, Susanne MOHR, Valentina D'ARIENZO
-
Publication number: 20210147535Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: ApplicationFiled: August 21, 2020Publication date: May 20, 2021Inventors: Lykke PEDERSEN, Hassan JAVANBAKHT, Malene JACKEROTT, Søren OTTOSEN, Souphalone LUANGSAY
-
Patent number: 10953034Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.Type: GrantFiled: October 16, 2018Date of Patent: March 23, 2021Assignee: HOFFMANN-LA ROCHE INC.Inventors: Susanne Kammler, Anaïs Lopez, Henrik Mueller, Søren Ottosen, Lykke Pedersen
-
Publication number: 20210054381Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.Type: ApplicationFiled: September 4, 2020Publication date: February 25, 2021Applicant: Hoffmann-La roche Inc.Inventors: Hassan JAVANBAKH, Søren OTTOSEN, Morten LINDOW
-
Patent number: 10829555Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: GrantFiled: April 2, 2020Date of Patent: November 10, 2020Assignee: Hoffman-La Roche Inc.Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
-
Patent number: 10767181Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.Type: GrantFiled: August 2, 2019Date of Patent: September 8, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Hassan Javanbakh, Søren Ottosen, Morten Lindow
-
Patent number: 10745480Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: GrantFiled: October 25, 2019Date of Patent: August 18, 2020Assignee: Hoffmann-La Roche, Inc.Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
-
Publication number: 20200247884Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: ApplicationFiled: April 2, 2020Publication date: August 6, 2020Inventors: Lykke PEDERSEN, Hassan JAVANBAKHT, Malene JACKEROTT, Søren OTTOSEN, Souphalone LUANGSAY
-
Publication number: 20200157546Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.Type: ApplicationFiled: October 28, 2019Publication date: May 21, 2020Inventors: Rubén Alvarez Sánchez, Roberto Iacone, Peter Hagedorn, Susanne Kammler, Søren Ottosen, Sindri Traustason, Heidi Rye Hudlebusch, Lykke Pedersen, Marco Berrera, Andreas Dieckmann
-
Publication number: 20200147123Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.Type: ApplicationFiled: October 23, 2019Publication date: May 14, 2020Applicant: HOFFMAN-LA ROCHE INC.Inventors: Susanne KAMMLER, Anaïs LOPEZ, Henrik MUELLER, Søren OTTOSEN, Lykke PEDERSEN
-
Publication number: 20200048344Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: ApplicationFiled: October 25, 2019Publication date: February 13, 2020Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
-
Publication number: 20200024605Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.Type: ApplicationFiled: August 2, 2019Publication date: January 23, 2020Applicant: Hoffmann-La roche Inc.Inventors: Hassan Javanbakh, Søren Ottosen, Morten Lindow
-
Patent number: 10421967Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.Type: GrantFiled: May 15, 2015Date of Patent: September 24, 2019Assignee: HOFFMANN-LA ROCHE INC.Inventors: Hassan Javanbakh, Søren Ottosen, Morten Lindow
-
Publication number: 20190216846Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection, wherein a compound that reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7) is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. The invention also provides for inhibitors of PAPD5 or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.Type: ApplicationFiled: June 19, 2017Publication date: July 18, 2019Applicant: HOFFMANN-LA ROCHE INC.Inventors: Hassan JAVANBAKHT, Søren OTTOSEN, Lykke PEDERSEN, Henrik MUELLER
-
Publication number: 20190111073Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.Type: ApplicationFiled: October 16, 2018Publication date: April 18, 2019Applicant: Roche Innovation Center Copenhagen A/SInventors: Susanne Kammler, Anaïs Lopez, Henrik Mueller, Søren Ottosen, Lykke Pedersen
-
Publication number: 20190055564Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.Type: ApplicationFiled: May 29, 2018Publication date: February 21, 2019Inventors: Rubén Alvarez Sánchez, Roberto Iacone, Peter Hagedorn, Susanne Kammler, Søren Ottosen, Sindri Traustason, Heidi Rye Hudlebusch, Lykke Pedersen, Marco Berrera, Andreas Dieckmann
-
Publication number: 20170283496Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.Type: ApplicationFiled: March 14, 2017Publication date: October 5, 2017Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
-
Publication number: 20160010093Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.Type: ApplicationFiled: May 15, 2015Publication date: January 14, 2016Applicant: HOFFMANN-LA ROCHE INC.Inventors: Hassan JAVANBAKH, Søren OTTOSEN, Morten LINDOW
-
Publication number: 20150368642Abstract: The invention provides LNA therapeutics oligonucleotide carbohydrate conjugates with considerably enhanced potency, extended therapeutic index and reduced toxicity.Type: ApplicationFiled: January 30, 2014Publication date: December 24, 2015Inventors: Nanna ALBÆK, Henrik Frydenlund HANSEN, Susanne KAMMLER, Jacob RAVN, Henrik ØRUM, Mark TURNER, Monika KRAMPERT, Philipp HADWIGER, Søren OTTOSEN, Morten LINDOW